From other sites
at Investor's Business Daily (Jan 20, 2015)
at Zacks.com (Jan 20, 2015)
at CNBC.com (Jan 20, 2015)
Pre-Market Earnings Report for January 20, 2015 : JNJ, MS, DAL, HAL, BHI, MTB, RF, IGTE, ATI, EDU, MTG, SAPat Nasdaq.com (Jan 16, 2015)
at CNBC.com (Jan 16, 2015)
at Zacks.com (Jan 16, 2015)
at Nasdaq.com (Jan 16, 2015)
at MarketWatch.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
at CNBC.com (Jan 15, 2015)
- Johnson & Johnson generated solid results in spite of a strengthening dollar and declines in sales of Olysio.
- Dozens of new products coming from all three business segments should contribute to growth going forward, with many other consumer and medical device products having been recently released.
- The company remains a market leader, with 70% of sales coming from products with either a #1 or #2 market share position.
- At its current price, J&J offers investors long-term returns of 7-9%.
Johnson & Johnson Is Not Overvalued - This Company Could Have 35% Upside From Here
- I disagree that Johnson & Johnson (JNJ) is overvalued.
- Should the company achieve a 10% growth rate in dividends and earnings year-on-year, we could well see a 35% upside from current levels.
- In my opinion, Johnson & Johnson is uniquely positioned to capitalise on growth in emerging markets.
Johnson & Johnson: No Real Earnings Growth Since 2007; And Don't Ignore Special Items
- Johnson & Johnson has achieved significant and sustained growth for over a century.
- But detailed analysis shows no real growth in either revenue or earnings over the last 6 to 8 years. JNJ has virtually stood still for this period.
- Adjusting for “Special Items” is a potential trap if these costs are not viewed as being of a real and ongoing nature.
Johnson & Johnson: 'Slightly Overvalued' Is No Reason To Sell
- Recently an author indicated that Johnson & Johnson was slightly overvalued, further suggesting this would be a reason to sell.
- This article looks at this ideology generally, bringing attention to the potential for mental folly.
- It’s important to recognize one’s limitations, as forecasting provides an imperfect range of possibilities.
Johnson & Johnson Is Slightly Overvalued, Time To Sell This Drug Maker
- JNJ's share price is overvalued by 8% relative to its fair intrinsic value.
- JNJ's outlook for growth has significantly decelerated, and it is too big to succeed.
- JNJ still has a strong financial position and solid dividend growth.
Johnson & Johnson Q4 Results: Focusing On The Controllable Factors
- JNJ reported its 4Q14 financial results with EPS $1.27, up 2.4% from the same quarter a year earlier.
- The sales declined 0.6% to $18.3bn due to FX headwinds. Sales could have shown 3.9% growth on a constant currency basis.
- The company continues to invest in its future growth drivers.
Update: Johnson & Johnson - Slightly Higher Valuation But Still Solid
- Johnson & Johnson announced full-year 2014 earnings results.
- The company continues to show improvement.
- Although the valuation is higher today as compared to last year, shares still offer a reasonable opportunity in a solid company.
Johnson & Johnson Finding Growth A Little Harder Now
- Johnson & Johnson posts a broad-based miss, with weakness in pharma undermining margins and devices still struggling to log meaningful revenue momentum.
- Johnson & Johnson's robust cash generation can support ongoing dealmaking to augment the long-term prospects of the drug and device businesses.
- Should healthcare stocks pull back, or the market overreact to what is likely to be a tougher stretch in JNJ's drug business, these shares would be an attractive long-term buy.
Update: Johnson & Johnson Drops On Compressed Margins, But For The Wrong Reasons
- JNJ saw some substantial negative impacts from changes in exchange rates.
- The year-over-year comparison on a GAAP basis looks terrible, but that was largely a taxation issue.
- The pre-tax margins under GAAP were slightly compressed, but the compression was tied to increased R&D spending.
- The results of decreased margins were in line with my expectations, but excluding R&D the margins improved.
- My bearish thesis of underperformance for JNJ is softened by the R&D, but remains intact due to expectations on headwinds from exchange rates.
- J&J sold off 3% after reporting 2014 results, and is about 10% off its 52-week high, even though the company realized strong growth across its key markets.
- The market is irrationally punishing J&J for unfavorable currency fluctuations. But currencies are outside a company's control, and should not take precedence over core fundamentals.
- J&J's business remains strong, and thanks to its recent dip, the stock is attractive to both value and income investors.
Johnson & Johnson: 31 Consecutive EPS Increases & Counting
- Johnson & Johnson's full year and 4th quarter results came out this morning.
- Johnson & Johnson saw EPS increase 8.2% for its full year 2014.
- The company continues to see strong growth in its Worldwide Pharmaceutical segment.
Will Johnson & Johnson Top The Whisper Number This Quarter?
- The whisper number is $1.29, three cents ahead of the analysts' estimate.
- JNJ has a 62% positive surprise history (having topped the whisper in 32 of the 52 earnings reports for which we have data).
- The overall average post earnings price move is "as expected" but limited (beat the whisper number and see limited strength, miss and see limited weakness) when the company reports earnings.
- Johnson & Johnson (JNJ) is slated to report 4Q 2014 earnings before the opening bell on Tuesday, January 20th.
- Adjusted Earnings Per Share: The current Street estimate is $1.26 (range $1.21 to $1.29).
- Revenues: Analysts expect an increase of 1.1% y/y to $18.56 bln (range $18.29 bln to $18.90 bln).
The Next Stock I Would Build A Retirement Portfolio Upon At Any Age
- Dependability of continuous dividends paid and increased creates a more secure financial future no matter what age you start a portfolio.
- A dividend aristocrat has proven its ability to reward shareholders for more than a quarter of a century.
- When a dividend aristocrat stock is in the heart of an ongoing growth industry, the financial rewards can be spectacular.
- Recently I detailed how one might go about generating $100 per month from AT&T.
- This article looks at the same process for Johnson & Johnson, a lower-yielding, but faster-growing company.
- In the end it comes down to your lasting preference and specific goals.
Have Johnson & Johnson Shares Pretty Much Peaked For 2015?
- JNJ was wise not to listen to Goldman in 2012.
- But the landscape has changed.
- Should they revisit that recommendation in 2015?
- JNJ is one of the best run companies in the world - with business segment diversification and global diversification.
- JNJ is a dividend champion that has paid and raised dividends for 52 years. The 5-yr DGR stands at 7.4%.
- The changing global demographics make JNJ one of the best positioned companies in the world.
Johnson & Johnson: Well Positioned In The Healthcare Industry
- Johnson & Johnson is a leader in the pharmaceutical, medical device and consumer products industries.
- In mid-October the company announced third quarter sales of $18.5 billion, up 5.1% when compared to the third quarter of 2013, with domestic sales increasing 11.6%.
- The company increased its earnings guidance for full-year 2014 to $5.92 to $5.97 per share.
Johnson & Johnson: Still A Great Income Stock, If A Bit Expensive
- JNJ's valuation has become a bit stretched.
- The stock's record of income is still one of the best out there.
- I like JNJ at $100 or less for its steady dividend raises and earnings visibility.
Thu, Jan. 22, 3:45 AM
- After lawyers for both companies made final presentations on Wednesday, Johnson & Johnson's (NYSE:JNJ) multibillion-dollar trial with Boston Scientific (NYSE:BSX) over its purchase of device maker Guidant now lies in the hands of a federal judge.
- As Guidant’s successor, J&J is seeking more than $7.2B in damages and interest from Boston Scientific for violating clauses included under their agreement to combine in 2004.
- Previously: J&J, Boston Scientific $5B trial to begin Thursday (Nov. 19 2014)
Tue, Jan. 20, 8:44 AM
- Johnson & Johnson (NYSE:JNJ) notable changes in Q4 by segment ($M):
- Consumer (-3.9%): Women's Health (-11.5%); Baby Care: (-10.4%); Wound Care: (-6.2%).
- Pharmaceutical (+9.6%); Immunology (+7.3%), Simponi/Simponi Aria: 346 (+36.2%), Stelara: 545 (+30.7%), Remicade: 1,672 (-2.3%).
- Infectious Diseases (+13.9%); Olysio/Sovriad: 321 (+999%), Edurant: 90 (+23.3%), Prezista: 448 (-2.8%), Other: 212 (-24.6%), Incivo: 5 (-95.3%).
- Neuroscience: 1,651 (unch); Invega Sustenna/Xeplion: 418 (+19.4%), Invega: 161 (+4.5%), Other: 609 (-7.3%), Risperda Consta: 294 (-8.4%).
- Oncology: 1,212 (+8.9%); Other: 199 (+111.7%), Zytiga: 595 (+20.2%), Velcade: 418 (-20.2%).
- Other: 1,482 (+28.1%), Xarelto: 428 (+57.9%), Other: 752 (+29.9%), Procrit/Eprex: 302 (-1.6%).
- Med Devices & Diag: 6,649 (-9.0%); Specialty Surgery/Other: 904 (+32.4%), Cardiovascular Care: 558 (+4.5%), Orthopedics: 2,441 (-0.6%), Surgical Care: 1,572 (-4.1%), Diabetes Care: 514 (-8.7%), Vision Care: 646 (-10.2%), Diagnostics: 14 (-97.0%).
Tue, Jan. 20, 8:21 AM
- Johnson & Johnson (NYSE:JNJ) Q4 results ($M): Total Revenues: 18,254 (-0.6%), Consumer: 3,606 (-3.9%), Pharmaceutical: 7,999 (+9.6%), Medical Devices & Diagnostics: 6,649 (-9.0%).
- Revenue by region: U.S.: 8,604 (+7.4%), Europe: 4,560 (-8.2%), W. Hemisphere ex. U.S.: 1,782 (-5.8%), Asia Pacific & Africa: 3,308 (-5.0%).
- COGS: 5,853 (-1.7%); R&D Expense: 2,635 (+9.3%); SG&A Expense: 5,822 (-1.6%); Net Income: 2,521 (-28.4%); EPS: 0.89 (-27.6%); Gross Profit: 12,401 (unch); COGS: 32.1% (-1.2%); Gross Margin: 67.9% (+0.6%); Operating Income: 3,944 (-3.1%); Operating Income Yield: 21.6% (-2.6%); Net Earnings Yield: 13.8% (-28.0%).
- 2015 non-GAAP EPS guidance: $6.12 - 6.27.
Tue, Jan. 20, 7:51 AM| 2 Comments
Mon, Jan. 19, 5:53 PM
- The FDA grants Priority Review status to Janssen Research & Development's (NYSE:JNJ) New Drug Application (NDA) for a three-month formulation of paliperidone palmitate for the treatment of adult patients with schizophrenia.
- Priority Review provides for a shorter review clock (six months) compared to the normal time frame of 10 months.
- Previously: J&J submits NDA for three-month antipsychotic (Nov. 20, 2014)
Mon, Jan. 19, 5:30 PM
Mon, Jan. 19, 5:11 PM
- As expected, the European Commission approves Novartis' (NYSE:NVS) Cosentyx (secukinumab) as a first-line systemic treatment for adult patients with moderate-to-severe psoriasis. It is the first interleukin-17A inhibitor cleared in Europe.
- Cosentyx is also cleared for sale in Australia and Japan. FDA approval is imminent considering the unanimous positive vote by the Dermatologic and Ophthalmic Drugs Advisory Committee in October.
- Previously: Europe Ad Comm gives thumbs up to Novartis psoriasis drug (Nov. 21, 2014)
- Previously: Ad Comm backs approval of secukinumab (Oct. 21, 2014)
- Psoriasis-related tickers: (NYSE:JNJ) (NASDAQ:DERM) (NYSE:MRK) (NASDAQ:CELG) (NASDAQ:IDRA) (NYSE:HSP) (NYSEMKT:CANF) (NASDAQ:AMGN) (NYSE:AZN) (NYSE:PFE)
Fri, Jan. 16, 8:54 AM
- A consortia of global research institutions and non-government organizations has been formed to work with Janssen Pharmaceuticals (NYSE:JNJ) to accelerate the development of its Ebola vaccine. The Innovative Medicines Initiative intends to grant more than €100M to fund the development work. The project is delineated into three areas or topics:
- Topic 1: Vaccine development, Phases 1, 2 and 3. Consortia members: Janssen, London School of Hygiene and Tropical Medicine, Oxford University, Insititut National de la Sante et de la Recherche Medicale (INSERM), La Centre Muraz.
- Topic 2: Manufacturing capability: Janssen, Bavarian Nordic A/S, Vibalogics.
- Topic 3: Deployment and compliance of vaccination regimens: Janssen, London School of Hygiene and Tropical Medicine, Grameen Foundation, World Vision of Ireland.
- A recently-started Phase 1 trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Janssen, in partnership with Bavarian Nordic A/S (OTCPK:BVNRY), has produced more than 400K regimens of the prime-boost vaccine for use in large-scale trials that could begin as early as April.
- Ebola vaccine-related tickers: (NASDAQ:NLNK) (NYSE:MRK) (NYSE:GSK)
Thu, Jan. 15, 5:52 PM
- DepoMed (NASDAQ:DEPO) +3.7% AH after agreeing to acquire the U.S. license rights to the painkiller Nucynta from Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals for $1.05B.
- DEPO says it plans to reintroduce the drug, expand its sales force and promote Nucynta for both chronic pain and nerve damage caused by diabetes; DEPO says Nucynta has patent protection until 2022.
- DEPO, which previously projected 2014 sales of $232M-$242M, says the deal will increase its 2014 pro forma net product revenue guidance by ~2.5x.
Wed, Jan. 14, 9:13 AM
- Express Scripts' (NASDAQ:ESRX) success in containing the prices of new HCV therapies by pitting Gilead Sciences (NASDAQ:GILD) against AbbVie (NYSE:ABBV) is sending shock waves through the biotech/pharma industry. Most of the big players slumped yesterday as investors fear that ESRX's tactics will spread to other high cost areas like cancer and cholesterol.
- At JPM15 yesterday, CEO George Paz said that the new cholesterol-lowering post-statin PCSK9 inhibitors will be the next big opportunity to pit drug firms against each other in order to drive costs down. FDA clearance of the first two therapies, one from Amgen (NASDAQ:AMGN) and the other from Regeneron Pharmaceuticals (NASDAQ:REGN) (NYSE:SNY), is expected to occur at about the same time.
- The prices of emerging cancer therapies will also be in payers' crosshairs. Amgen's Blincyto, for example, costs $178,000 per standard course of treatment while Merck's (NYSE:MRK) Keytruda is close behind at $150,000.
- Related tickers: (NYSE:AZN) (NYSE:GSK) (NYSE:LLY) (ABBV) (NYSE:PFE) (NASDAQ:BIIB) (NYSE:ABT) (NASDAQ:CELG) (NYSE:BMY) (OTCQX:RHHBY) (NYSE:JNJ) (NYSE:NVS) (OTCPK:BAYRY)
Wed, Jan. 14, 8:25 AM
- Ziopharm (NASDAQ:ZIOP) jumps 50% premarket on robust volume in response to its announcement of an exclusive license deal with partner Intrexon (NYSE:XON) (+12%) with The University of Texas MD Anderson Cancer Center covering technology and intellectual property related to non-viral adoptive cellular cancer immunotherapies. The technologies originate from two researchers who have pioneered the design and clinical investigation of chimeric antigen receptor (CAR) T cell therapies for the potential treatment of cancer using non-viral gene integration platforms.
- The two researchers are Laurence Cooper, M.D., Ph.D, professor of pediatrics at MD Anderson who has expertise in immunotherapies and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota, who discovered and developed a system called Sleeping Beauty, a non-viral DNA plasmid-based gene transfer system.
- The deal brings the CAR-T technology together Intrexon's technology suite and Ziopharm's clinically tested RheoSwitch Therapeutic System interleukin-12 modules. Up to five CARs are expected to enter the clinic this year and off-the-shelf programming initiating in 2016.
- Under the terms of the agreement, MD Anderson will receive $100M from the companies in the form of $50M of common stock from each firm. In addition, the companies have committed $15M - 20M over each of the next three years for researching and developing the technologies.
- CAR-T therapies are the "next big thing" in cancer treatment.
- Related tickers: (NASDAQ:KITE) (NASDAQ:JUNO) (NASDAQ:AMGN) (NYSE:NVS) (NYSE:JNJ)
Tue, Jan. 13, 8:24 AM
- Janssen Biotech (NYSE:JNJ) enters into a license agreement with Vedanta Biosciences for the development and commercialization of VE202, a human microbiome modulator, that has demonstrated efficacy in preclinical models of autoimmune disease. Janssen will focus on the indication of inflammatory bowel disease (IBD).
- Under the terms of the agreement, Vedanta will receive an upfront payment and various milestones potentially up to $241M plus additional consideration related to commercialization. Vedanta may continue to explore other indications and licensing deals. Janssen may elect to expand its work into new areas under terms similar to the IBD indication.
Mon, Jan. 12, 9:46 AM
- Hospira (HSP) submits its Biologics License Application (BLA) to the FDA for Retacrit, a biosimilar to Amgen's (AMGN +1.3%) Epogen (epoetin alfa) and Janssen's (JNJ +0.5%) Procrit (epoetin alfa). The submission was actually made on December 16 under the new 351(k) approval pathway created by the Biologics Price Competition and Innovation Act of 2009.
- Last week, an FDA advisory committee voted in favor of the approval of Sandoz's BLA for its biosimilar to Amgen's Neupogen (filgrastim).
- Previously: FDA Ad Comm gives thumbs up to Sandoz biosimilar filgrastim (Jan. 7)
Mon, Jan. 12, 4:18 AM
- Boosting its Alzheimer's research efforts, Johnson & Johnson (NYSE:JNJ) has struck an up to $509M deal with Swiss biotech firm AC Immune to develop so-called anti-tau vaccines to treat Alzheimer's patients earlier in the disease.
- Tau is a protein known for forming tangles inside brain cells and is linked to cell death.
Fri, Jan. 9, 8:24 AM
- A Phase 3 trial evaluating the safety and efficacy of Portola Pharmaceuticals' (NASDAQ:PTLA) Breakthrough Therapy-designated anticoagulant antidote, andexanet alfa, met its primary primary endpoint of significantly and immediately reversing the steady-state anticoagulation activity of the Factor Xa inhibitor Xarelto (rivaroxaban) (NYSE:JNJ) when administered as an intravenous bolus.
- The second part of the trial assessing the safety and efficacy of a bolus plus continuous infusion of andexanet alfa to sustain reversal, is ongoing.
- Portola is developing the product for patients on Factor Xa inhibitors who are experiencing a major bleeding episode or who need emergency surgery.
- The company will present the full data set on Monday, March 16 at the American College of Cardiology's Annual Scientific Session in San Diego.
- PTLA is up 11% premarket on modest volume.
Thu, Jan. 8, 7:55 PM
- The FDA approves Daiichi-Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
- Edoxaban is an anticoagulant that inhibits factor Xa. It was approved in Japan in 2011 for the prevention of venous thromboembolism in patients undergoing total knee replacement surgery, total hip replacement surgery and hip fracture surgery.
- Anticoagulant-related tickers: (NASDAQ:ISIS) (NYSE:BAX) (NASDAQ:PTLA) (NASDAQ:MSLI) (NYSE:MRK) (NYSE:JNJ) (NASDAQ:MDCO) (NASDAQ:SCLN) (NYSE:PFE) (NYSE:BMY) (NYSE:AZN) (OTCPK:BAYRY)
JNJ vs. ETF Alternatives
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.
Other News & PR